Pliant Therapeutics Q1 net loss $47.0M; bexotegrast adaptive Phase 2b/3 accelerated

PLIANT THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.78

Net loss $47.0M in Q1 2024 vs $37.5M in Q1 2023; R&D expenses rose to $37.1M from $29.3M.
BEACON-IPF Phase 2b/3 adaptive design upsized to 360 patients; enrollment completion expected Q1 2025.
Phase 2a PET imaging trial completed; topline data on total lung collagen and FVC expected in weeks.
Oxford loan facility upsized by $50M to $150M; $30M drawn. Cash $483.9M funded through 2026.
Regulatory clearance for PLN-101325 Phase 1 in muscular dystrophy; Phase 1 of PLN-101095 in solid tumors ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income Net loss of $47.0 million.

Period: first quarter ended March 31, 2024
Net income: Net loss of $47.0 million
Result: reported results

Exact text from the filing

Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-24-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.